OncoMyx Therapeutics develops oncolytic immunotherapies to assist in creating an immune response and treat cancer.
OncoMyx Therapeutics has raised $50.0M in total funding. The most recent round was Series B. The last funding was announced in December 2021.
OncoMyx Therapeutics's investors include B Capital, Boehringer Ingelheim Venture Fund, Lumira Ventures, Delos Capital, Korea Investment Partners.
OncoMyx Therapeutics is headquartered in Phoenix, United States.
OncoMyx Therapeutics develops oncolytic immunotherapies to assist in creating an immune response and treat cancer.
OncoMyx Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"OncoMyx Therapeutics — Funding & Investors." VCBacked, December 9, 2021, https://www.vcbacked.co/company/oncomyx-therapeutics. Accessed August 13, 2026.
VCBacked. (2021). OncoMyx Therapeutics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/oncomyx-therapeutics
{{cite web |title=OncoMyx Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/oncomyx-therapeutics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated